Last updated on September 2018

Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

Brief description of study

The primary objective of the study is to determine whether pemafibrate administered twice daily will delay the time to first occurrence of any component of the clinical composite endpoint of:

  • nonfatal Myocardial Infarction (MI)
  • nonfatal ischemic stroke
  • hospitalization for unstable angina requiring unplanned coronary revascularization; or
  • Cardio Vascular (CV) death.

Detailed Study Description

A multi-regional clinical trial with participating sites planned in the following countries pending approval from the applicable oversight authorities:

  • Argentina
  • Brazil
  • Bulgaria
  • Canada
  • Colombia
  • Czech Republic
  • Denmark
  • France
  • Germany
  • Hungary
  • India
  • Israel
  • Japan
  • Mexico
  • Netherlands
  • Poland
  • Romania
  • Russian Federation
  • Slovakia
  • South Africa
  • Spain
  • Ukraine
  • United Kingdom
  • United States

Clinical Study Identifier: NCT03071692

Contact Investigators or Research Sites near you

Start Over

Senior Clinical Research Associate

Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
  Connect »

Senior Clinical Research Associate

Diabetes Medical Center
Tel Aviv, Israel
  Connect »

Senior Clinical Research Associate

Chaim Sheba Medical Center
Ramat Gan, Israel
  Connect »

Senior Clinical Research Associate

Wolfson Medical Center
Holon, Israel
  Connect »

Senior Clinical Research Associate

Rabin Medical Center-Beilinson Campus
Petach Tikva, Israel
  Connect »